排序方式: 共有1条查询结果,搜索用时 0 毫秒
1
1.
PACOURET G.; CHARBONNIER B.; CURIEN N. D.; MONASSIER J.P.; CRIBIER A.; MATERNE P.; BROCHIER MIREILLE L.; LETAC R.; HANSSEN M.; SACREZ A.; KULBERTUS H. 《European heart journal》1991,12(2):179-185
IRS II (Invasive reperfusion study II) was a multicentre randomizedtrial comparing the efficacy of a 25-min 30 U anistreplaseintravenous injection with a 1 500 000 U 60-min streptokinase(SK) intravenous infusion in acute myocardial infarction. 116patients were randomized within 6 h of onset of symptoms. Earlycoronary patency was assessable in 107 patients by coronaryangiogram performed 102 min after thrombolytic treatment (range:30297 min) in the anistreplase group and 93 min (range:22330 min) in the SK group. The early coronary patencyrate was significantly higher in the anistreplase group thanin the SK group: respectively, 70% (38/54) and 51% (27/53),P<0.05. Fifty patients had assessable coronary angiogramsat 90 min and 24 h. The 24-h patency rate was 92.3% (24/26)in the anistreplase group vs 87.5% (21/24) in the SK group.No early reocclusion occurred in the anistreplase group vs 15.4%(2/13) in the SK group (NS). Fibrinogen fell to 13.2 ±19.8%on anistreplase vs 9.4 ±10.3% on SK (NS). Bleeding complicationsoccurred in 12% (7/58) of treated patients in the anistreplasegroup vs 20.7% (13/58) in the SK group (NS). Two cerebrovascularaccidents occurred after thrombolytic treatment with anistreplase(3.4%) vs one after SK (1.7%) (NS). Thus, anistreplase is moreeffective than intravenous SK and easier to administer. 相似文献
1